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Preoperative serum lactate dehydrogenase (LDH) has been used as a prognostic indicator for patients with
hepatocellular carcinoma (HCC) treated with sorafenib or undergoing transcatheter arterial chemoembolization,
but its significance in predicting survival of HCC patients who received curative resection remains undefined. A
total of 683 patients with histopathologically confirmed HCC were enrolled in this study. The prognostic
significance of preoperative serum LDH was determined by Kaplan-Meier analysis and a Cox proportional hazards
regression model. The association between the preoperative serum LDH and clinicopathological parameters was
evaluated by the χ2 test or linear regression analysis when appropriate. Higher preoperative serum LDH level was
associated with worse prognosis. In a multivariate Cox proportional hazards analysis, the preoperative serum LDH
level could predict overall survival and recurrence independently. Higher preoperative serum LDH level is
associated with the elevated serum alpha-fetoprotein, the presence of hepatitis B surface antigen, larger tumor
size, the presence of macrovascular invasion, the advanced tumor–lymph node–metastasis stage, worse tumor
differentiation, and Child-Pugh B. Preoperative serum LDH level was an inexpensive, simple, convenient, and
routinely measured biomarker exhibiting a potential to select patients at high risk with poor clinical outcome for
appropriate treatment strategies.
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Hepatocellular carcinoma (HCC) is the sixth most common
malignancy with an increasing incidence and a dismal survival
[1,2]. It has high heterogeneity and is generally resistant to
chemotherapy and radiotherapy. Therefore, resection and liver
transplantation still remain the prior curative therapeutic options
for patients with HCC [3]. However, the postsurgical recurrence is
high, which reaches nearly 50% within 3 years. To date, although risk
factors and models associated with postsurgical recurrence have
attracted much interest and been widely explored, there is still a long
way for these new markers and models to be accepted and applicable
in the clinical practice [4]. Hence, it is vital to establish simple and
effective means to identify patients at high risk for recurrence and to
Table 1. Characteristics of HCC Patients in the Training and Validation Cohort
Variables Training Set Validation Set
n = 344 n = 339 P
No. % No. %
Age (years) .236
≤50 164 47.7 177 52.2
N50 180 52.3 162 47.8
Gender .252
Male 309 89.8 295 87.0
Female 35 10.2 44 13.0
HBsAg .467
Negative 47 13.7 53 15.6
Positive 297 86.3 286 84.4
AFP .483
≤25 ng/ml 130 37.8 137 40.4
N25 ng/ml 214 62.2 202 59.6
Tumor number .245
Single 293 85.2 299 88.2
Multiple 51 14.8 40 11.8
Tumor size .504
≤5 cm 182 52.9 188 55.5
N5 cm 162 47.1 151 44.5
Macrovascular invasion .206
Absent 330 95.9 331 97.6
Present 14 4.1 8 2.4
TNM stage .055
I-II 294 85.5 306 90.3
III-IV 50 14.5 33 9.7
Tumor differentiation .137
I-II 222 64.5 202 59.6
III-IV 118 34.3 136 40.1
Missing 4 1.2 1 0.3
Child-Pugh classification .830
A 335 97.4 331 97.6
B 9 2.6 8 2.4
Note: The differences in the clinicopathological parameters between the training set and the
validation set were evaluated using Mann-Whitney U two-independent-samples tests.
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such patients.
Lactate dehydrogenase (LDH) is a metabolic enzyme involved in
anaerobic glycolysis and regulated by the PI3K/Akt/mTOR path-
ways, the c-Myc oncogenic transcription factor, and tumor hypoxia/
necrosis [5,6]. It has been reported that LDHA, comprising
tetrameric subunit A of LDH, is not only involved in tumor
initiation but also plays an important role in tumor maintenance and
progression. LDH is a well-identified prognostic marker in multiple
malignancies, including colorectal cancer, breast cancer, lymphoma,
melanoma, renal cell carcinoma, and germ cell tumors [7–14].
Although the role of serum LDH levels in predicting global outcome
in HCC patients treated with sorafenib and HCC patients
undergoing transcatheter arterial chemoembolization (TACE) has
been confirmed, the clinical significance of LDH in HCC patients
who received curative resection has not yet been investigated [15,16].
In the present study, we first determined the best cutoff value of
preoperative serum LDH as a prognostic indicator for overall survival
(OS) in a group of HCC patients receiving curative resection (the
training cohort) and then validated the prognostic significance of
LDH with the same cutoff value on the survival in an independent
cohort (the validation cohort). We further evaluated the clinicopath-
ological roles of LDH in HCC. In general, our results showed that the
preoperative serum LDH is associated with metastasis, HCC
progression, and prognosis.
Materials and Methods
Patients
Six hundred and eighty-three patients with pathologically
confirmed HCC who underwent curative resection, defined as
complete macroscopic removal of the tumor, between January 2008
and June 2012 at the Cancer Center of Sun Yat-sen University in
Guangzhou were enrolled in this study. Written informed consent
was obtained from all patients before enrollment in the study. This
study was performed in strict accordance with the ethical guidelines of
the Declaration of Helsinki, and the protocol was approved by the
Institutional Review Boards of the Cancer Center.
Each of the patients was absent of any preoperative anticancer
treatment and any other malignancies. The clinical stage was
determined according to the Union for International Cancer
Control/American Joint Committee on Cancer tumor–lymph
node–metastasis (TNM) classification system (seventh edition).
Tumor differentiation was graded according to the Edmondson-
Steiner classification. The clinicopathological features of all patients
were summarized in Table 1.
Patients were followed postoperatively with regular surveillance for
recurrence basing on the physical examination, the liver function,
serum alpha-fetoprotein (AFP) level, abdominal ultrasonography, and
chest radiography. When tumor recurrence or metastasis was
suspected, further examinations, such as computed tomography and
hepatic angiography, were performed. Biopsies were obtained when
necessary. Patients with confirmed recurrence received further
treatment, including a second liver resection, TACE, radiofrequency
ablation, or percutaneous ethanol injection, depending on the
location of the tumor and the liver function of the patient [17].
OS was defined as the interval (in months) from the date of surgery
to the date of death or from the date of surgery to the last follow-up
visit. Disease-free survival (DFS) was defined as the interval betweenthe date of surgery and the diagnosis of recurrence or between the date
of surgery and the last observation if no recurrence was observed. This
study was censored on 31 December 2014.
Serum LDH Level
Blood samples were collected within one month preoperation.
LDH level was measured by spectrophotometric enzyme assay with
LDH reagent (Wako Pure Chemical Industries, Ltd., Osaka, Japan)
using Hitachi 7600 automated chemistry analyzer (Hitachi, Ltd.,
Tokyo, Japan) within 2 hours after collection.
Statistical Analyses
The optimal cutoff prognostic value of LDH for OS was estimated
by the receiver operating curve analysis, and its prognostic value was
confirmed in the validation cohort. The differences in the
clinicopathological parameters between the training cohort and the
validation cohort were evaluated using Mann-Whitney U two-inde-
pendent-samples tests.
Correlations between the clinicopathological parameters and LDH
level were determined by the χ2 test or linear regression analysis when
appropriate. Survival was estimated by the Kaplan-Meier method and
compared using the log-rank test. Univariate and multivariate
analyses of prognostic factors for OS or DFS were performed using
the Cox proportional hazards model. A value of P b .05 was
considered statistically significant. Statistical analyses were performed
with SPSS software (version 16.0; SPSS Inc., Chicago, IL).
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Patient Characteristics
The data of 344 patients from January 2008 to December 2009
were used for the training cohort. The data of 339 patients since
January 2010 to June 2012 were enrolled as the validation cohort.
There was no significant difference in age, gender, hepatitis B
surface antigen (HBsAg), serum AFP level, tumor number, tumor
size, macrovascular invasion, TNM stage, tumor differentiation, and
Child-Pugh classification between the training and validation cohorts.
The characteristics of the participants in the training and the
validation cohorts are shown in Table 1.
The Cutoff Prognostic Value for LDH
The optimal cutoff value of serum LDH for OS was estimated as
188 U/L in the training cohort by the receiver operating curveFigure 1. Higher preoperative serum LDH level predicted poor surviva
in predicting OS (A, C, and E) and DFS (B, D, and F) in HCC patients enr
in the total test set (E and F) was estimated by the Kaplan-Meier meanalysis, with the area under the curve as 0.626 and 95% confidence
interval (CI) as 0.564 to 0.689.
Survival Analysis
The median duration of follow-up for the total test set was 41
months (range, 1-86 months). Of the 683 patients examined during
the follow-up period, 168 patients (24.6%) died, 326 patients
(47.7%) were diagnosed with tumor recurrence, and 333 patients
(48.8%) remained alive without recurrence. The median OS and
DFS for the whole cohort were 40 and 16 months, respectively.
To investigate whether preoperative serum LDH level is associated
with the clinical outcome of HCC patients, Kaplan-Meier cumulative
survival curves were first plotted in the training set using the log-rank
statistic to compare survival rates. As shown in Figure 1A and 1B,
survival was profitable in the patients with a lower level of LDH. The
OS (median survival, 60 months) and DFS (median survival, 23l in HCC patients. The significance of preoperative serum LDH level
olled in the training set (A and B), in the validation set (C and D), and
thod and compared by the log-rank test.
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compared with patients with a higher level of LDH (median survival,
40 months for OS and 10 months for DFS, respectively). Elevated
serum LDH level was also associated with worse OS and DFS in the
validation set and the total test set (P b .0001, Figure 1).
Multivariate Cox Proportional Hazards Analysis
To investigate whether preoperative LDH level serves as an
independent predictors of OS and DFS, a multivariate Cox
proportional hazards analysis was performed, and those variables
that were associated with survival by univariate analysis were adopted
as covariates (Table 2). In the training set, tumor number, tumor size,
Child-Pugh classification, and macrovascular invasion remained
independently associated with OS in the multivariate Cox propor-
tional hazards analysis (P = .050, .001, .001, and .022, respectively).
The serum LDH level predicted OS independent of these clinical
factors [hazard ratio (HR), 1.687; 95% CI, 1.131-2.516; P = .010;
Table 2]. HBsAg, tumor number, tumor size, and macrovascular
invasion served as independent prognostic factors for DFS in the
training set. However, the serum LDH could not independently
predict recurrence in this cohort.
In the validation set, the multivariate Cox proportional hazards
regression analysis also demonstrated that the serum LDH level could
predict OS independent of tumor number, tumor size, andTable 2. Univariate and Multivariate Analyses of Variables Associated with Survival and Recurrence
OS
Univariate Multivariate
Variables P HR 95% CI
Low
Training set
Age: N50 vs ≤50 years .044 1.353 0.902
Gender: male vs female .775
HBsAg: positive vs negative .239
AFP: N25 vs ≤25 ng/ml .008 1.447 0.929
Tumor number: multiple vs single .028 1.628 0.999
Tumor size: N5 vs ≤5 cm .000 2.003 1.312
Tumor differentiation: III-IV vs I-II .130
Child-Pugh classification: B vs A .000 3.452 1.608
Macrovascular invasion: present vs absent .000 2.321 1.131
LDH: N188 vs ≤188 U/L .000 1.687 1.131
Validation set
Age: N50 vs ≤50 years .804
Gender: male vs female .236
HBsAg: positive vs negative .092
AFP: N25 vs ≤25 ng/ml .029 1.379 0.802
Tumor number: multiple vs single .000 2.880 1.649
Tumor size: N5 vs ≤ 5 cm .000 3.404 1.863
Tumor differentiation: III-IV vs I-II .030 1.432 0.870
Child-Pugh classification: B vs A .024 1.031 0.365
Macrovascular invasion: present vs absent .000 3.246 1.253
LDH: N188 vs ≤188 U/L .000 2.553 1.489
Total test set
Age: N50 vs ≤50 years .148
Gender: male vs female .606
HBsAg: positive vs negative .041 1.407 0.840
AFP: N25 vs ≤25 ng/ml .001 1.347 0.952
Tumor number: multiple vs single .000 1.996 1.383
Tumor size: N5 vs ≤5 cm .000 2.445 1.727
Tumor differentiation: III-IV vs I-II .013 1.227 0.896
Child-Pugh classification: B vs A .000 2.281 1.249
Macrovascular invasion: present vs absent .000 2.586 1.462
LDH: N188 vs ≤188 U/L .000 1.865 1.359
Note: Cox proportional hazards regression model; variables associated with survival by univariate anamacrovascular invasion (HR, 2.553; 95% CI, 1.489-4.337; P =
.001; Table 2) and predict recurrence independent of tumor number,
tumor size, and Child-Pugh classification (HR, 1.711; 95% CI,
1.621-3.699; P = .005; Table 2).
In the total test set, the serum LDH level could predict OS
independent of tumor number, tumor size, Child-Pugh classification,
and macrovascular invasion (HR 1.865; 95% CI, 1.359-2.561; P b
.001; Table 2) and predict recurrence independent of HBsAg, serum
AFP level, tumor number, tumor size, Child-Pugh classification, and
macrovascular invasion (HR 1.446; 95% CI, 1.138-1.837; P = .003;
Table 2). These results showed that the serum LDH level was an
independent prognostic factor for both OS and recurrence.
Prognostic Significance of Preoperative LDH in the
Low-Risk Subgroups
We then assessed the prognostic value of the serum LDH level in
various low-risk subgroups in the total test set. As shown in
Figures 2A and 3A, in patients with AFP ≤ 25 ng/ml, patients with
LDH N 188 U/L had a shorter time to death (median of 36 vs 46
months, P b .0001) and recurrence (median of 15 vs 24 months, P =
.0002) than those patients with LDH ≤ 188 U/L. Similar results that
high LDH level was associated with worse OS (Figure 2, B–F) and
DFS (Figure 3, B–F) were also obtained in the rest of low-risk
subgroups, including the cohort of patients without HBsAg, within HCC Patients
DFS
Univariate Multivariate
P P HR 95% CI P
High Low High
2.03 .144 .495 NA
NA .105 NA
NA .046 1.636 1.020 2.626 .041
2.254 .102 .014 1.311 0.962 1.788 .087
2.653 .050 .000 1.929 1.331 2.796 .001
3.057 .001 .000 1.689 1.231 2.316 .001
NA .278 NA
7.41 .001 .254 NA
4.766 .022 .000 2.226 1.109 4.467 .024
2.516 .010 .001 1.263 0.916 1.742 .154
NA .151 NA
NA .584 NA
NA .023 1.595 0.900 2.826 .109
2.372 .245 .005 1.366 0.946 1.971 .096
5.028 .000 .000 2.729 1.788 4.166 .000
6.217 .000 .000 1.989 1.369 2.890 .000
2.357 .157 .004 1.259 0.886 1.789 .198
2.911 .954 .000 2.989 1.271 7.030 .012
8.405 .015 .000 2.338 0.993 5.502 .052
4.377 .001 .000 1.711 1.621 3.699 .005
NA .671 NA
NA .118 NA
2.358 .195 .003 1.654 1.144 2.390 .007
1.907 .092 .000 1.285 1.008 1.640 .043
2.881 .000 .000 2.212 1.673 2.923 .000
3.459 .000 .000 1.778 1.400 2.259 .000
1.679 .202 .005 1.169 0.924 1.479 .193
4.165 .007 .002 1.993 1.105 3.594 .022
4.575 .001 .000 2.258 1.323 3.852 .003
2.561 .000 .000 1.446 1.138 1.837 .003
lysis were adopted as covariates in multivariate analyses. NA, not applicable.
Figure 2. High preoperative serum LDH level predicted poor OS in the low-risk subgroups of HCC. The significance of preoperative serum
LDH level in predicting OS in the cohort of HCC patients with AFP ≤ 25 ng/ml (A), with absence of HBsAg (B), with single tumor (C), with
tumor size ≤ 5 cm (D), with absence of macrovascular invasion (E), and with TNM stage I to II (F) were estimated by the Kaplan-Meier
method and compared by the log-rank test. PVTT, portal vein tumor thrombus.
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invasion, and with TNM stage I to II. These data demonstrated that
serum LDH level served as an effective survival predictor even in the
low-risk subgroups.
Preoperative Serum LDH Level Was Associated with
Clinicopathological Features
To determine if there were any significant associations between the
clinical characteristics and preoperative serum LDH level, the χ2
analysis was performed. As shown in Table 3, higher preoperative
serum LDH level was correlated with the presence of HBsAg (P =
.038), tumor size (P = .000), macrovascular invasion (P = .019),
TNM stage (P = .001), tumor differentiation (P = .007), and
Child-Pugh classification (P = .008). In addition, serum LDH levelwas positively correlated with serum AFP using linear regression
analysis (Figure 4).
Taken together, higher preoperative serum LDH level was implicated
in determining a worse prognosis for both OS andDFS in HCC patients
following hepatectomy.This simple, inexpensive, and routinelymeasured
marker exhibits a potential to select patients at high risk with poor clinical
outcome for appropriate treatment strategies.
Discussion
In the present study, an elevated serum LDH level was independently
associated with poor OS and DFS in a large cohort of 683 HCC
patients with hepatectomy, even in the low-risk subgroups. In
addition, higher preoperative serum LDH level was also positively
correlated with increased serum AFP level. Preoperative serum LDH
Figure 3. High preoperative serum LDH level predicted poor DFS in the low-risk subgroups of HCC. The significance of preoperative
serum LDH level in predicting DFS in the cohort of HCC patients with AFP ≤ 25 ng/ml (A), with absence of HBsAg (B), with single tumor
(C), with tumor size ≤ 5 cm (D), with absence of macrovascular invasion (E), and with TNM stage I to II (F), were estimated by the
Kaplan-Meier method and compared by the log-rank test. PVTT, portal vein tumor thrombus.
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HBsAg, larger tumor size, presence of macrovascular invasion, advanced
TNM stage, worse tumor differentiation, and Child-Pugh B.
Although mounting evidence confirmed LDH as an indirect
marker of tumor hypoxia, angiogenesis and worse prognosis, the role
of LDH in a large cohort of HCC patients with hepatectomy has
never been explored. Scartozzi et al. retrospectively evaluated 114
patients and showed that elevated serum LDH was a poor prognostic
factor for HCC patients undergoing TACE. Faloppi et al.
demonstrated an independent prognostic significance for elevated
serum LDH in 78 patients treated with sorafenib. However, the role
of LDH in HCC patients with hepatectomy has never been referred
in both studies. In addition, the cases enrolled in both studies were
very small. To the best of our knowledge, the present study is thelargest one validating the prognostic value of serum LDH level in
HCC patients with hepatectomy.
This study demonstrated not only that a preoperative serum LDH
level is a prognostic indicator associated with DFS and OS but also
that it is an important prognostic indicator for clinical subgroups of
patients at low risk of tumor recurrence and tumor-related death,
including those patients with AFP ≤ 25 ng/ml, without HBsAg, with
single tumor, with tumor size ≤ 5 cm, with absence of macrovascular
invasion, and with TNM stage I to II.
To date, the biological link between LDH, hypoxia, and the
angiogenesis pathway through the abnormal activation of HIF-1α is
well established. In addition, myc and PI3K/Akt/mTOR pathways
have also been demonstrated to regulate cellular LDH expression
levels at translational and transcriptional levels. Therefore, elevated
Table 3. Association of Preoperative Serum LDH Level with Clinicopathological Parameters
Variables LDH P
Low (≤188 U/L) High (N188 U/L)
Age (years) .168
≤50 236 105
N50 219 123
Gender .255
Male 407 197
Female 48 31
HBsAg .038
Negative 76 24
Positive 379 204
Tumor number .190
Single 400 192
Multiple 55 36
Tumor size .000
≤5 cm 299 71
N5 cm 156 157
Macrovascular invasion .019
Absent 446 215
Present 9 13
TNM stage .001
I-II 414 186
III-IV 41 42
Tumor differentiation .007
I-II 299 125
III-IV 153 101
Missing 3 2
Child-Pugh classification .008
A 449 217
B 6 11
Note: Correlations between the clinicopathological parameters and LDH level were determined by
the χ2 test.
Translational Oncology Vol. 8, No. 6, 2015 Zhang et al. 503serum LDH level may not only represent tumor hypoxia and/or
angiogenesis but also be present along with abnormal activation of the
oncogenic pathways. However, the presence of other systemic diseases
should be carefully considered if the serum level of LDH increased
because it is also known as a nonspecific marker.
In conclusion, higher preoperative serum LDH level was implicated in
determining a worse prognosis for both OS and DFS in HCC patients
following hepatectomy.This simple, inexpensive, and routinelymeasuredFigure 4. Positive association between preoperative serum LDH
and AFP level in HCC patients. Preoperative serum LDH level was
plotted against AFP level from the same patient. Linear regression
analysis showed significant correlation between the preoperative
serum LDH and AFP level.marker exhibits a potential to select patients at high risk with poor clinical
outcome for appropriate treatment strategies.
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